PRIZE Trial is global news in the medical media

The PRIZE Trial

'Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial'

Methods

We will assess the efficacy and safety of adjunctive treatment with oral zibotentan (10 mg daily) in patients with microvascular angina and assess whether rs9349379 (minor G allele; population prevalence ~36%) acts as a theragnostic biomarker of the response to treatment with zibotentan.

The PRIZE trial is a prospective, randomized, double-blind, placebo-controlled, sequential cross-over trial. The study population will be enriched to ensure a G-allele frequency of 50% for the rs9349379 SNP. The participants will receive a single-blind placebo run-in followed by treatment with either 10 mg of zibotentan daily for 12 weeks then placebo for 12 weeks, or vice versa, in random order.

 scientific image - prize trial

Conclusion

PRIZE invokes precision medicine in microvascular angina. Should our hypotheses be confirmed, this developmental trial will inform the rationale and design for undertaking a larger multicenter trial.

Results

Dr Andrew Morrow and colleagues, say results show that "angina patients without obstructive coronary disease have unmet clinical needs, and disease-modifying therapies are urgently needed".

The research was presented on August 28 at the European Society of Cardiology Congress 2020, and made global news in the medical media:

https://www.medscape.com/viewarticle/936913

Link to PRIZE study

 


First published: 4 December 2020